Literature DB >> 15121164

FuGENE 6 Transfection Reagent: the gentle power.

Linda B Jacobsen1, Susan A Calvin, Kim E Colvin, MaryJo Wright.   

Abstract

FuGENE 6 Transfection Reagent has been commercially available since 1997. Since that time, its popularity has increased due to its ease of use, minimal to no cytotoxicity, and the high level of transfection in many different cell lines. FuGENE 6 Transfection Reagent is gentle on the cells. Adherent cells can be trypsinized and transfected by the DNA:FuGENE 6 reagent complex prior to plating, making it a strong candidate for high throughput applications. Additionally, low cell numbers can be transfected in 96-well plates. As with most reagents, the complex formation step is critical and special handling is required because the reagent is supplied in 80% ethanol. For example, contact with plastic must be avoided as inhibitors of transfection can leach from some plastics. We investigated parameters that have been reported to affect the transfection efficiency including the use of common antibiotics, passage level of the cells, and length of time for complex formation. These parameters are often cell line dependent and can be optimized to increase transfection efficiency for a specific cell line. Copyright 2003 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15121164     DOI: 10.1016/j.ymeth.2003.11.002

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  18 in total

1.  Exposure to dsRNA elicits RNA interference in Brachionus manjavacas (Rotifera).

Authors:  Terry W Snell; Tonya L Shearer; Hilary A Smith
Journal:  Mar Biotechnol (NY)       Date:  2010-05-12       Impact factor: 3.619

2.  Autophagosome formation during varicella-zoster virus infection following endoplasmic reticulum stress and the unfolded protein response.

Authors:  John E Carpenter; Wallen Jackson; Luca Benetti; Charles Grose
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

3.  Reproducible transfection in the presence of carrier DNA using FuGENE6 and Lipofectamine2000.

Authors:  Takao Susa; Takako Kato; Yukio Kato
Journal:  Mol Biol Rep       Date:  2007-05-17       Impact factor: 2.316

4.  Primary culture of alveolar epithelial type II cells and its bionomic study.

Authors:  Xuemei Shi; Huilan Zhang; Shengdao Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12

5.  Interplay between Affinity and Valency in Effector Cell Degranulation: A Model System with Polcalcin Allergens and Human Patient-Derived IgE Antibodies.

Authors:  Gintare Bucaite; Tara Kang-Pettinger; Jorge Moreira; Hannah J Gould; Louisa K James; Brian J Sutton; James M McDonnell
Journal:  J Immunol       Date:  2019-08-28       Impact factor: 5.422

6.  Aire regulates the expression of differentiation-associated genes and self-renewal of embryonic stem cells.

Authors:  Bin Gu; Jiarong Zhang; Qi Chen; Bo Tao; Wei Wang; Yang Zhou; Liangbiao Chen; Yusen Liu; Ming Zhang
Journal:  Biochem Biophys Res Commun       Date:  2010-03-10       Impact factor: 3.575

7.  A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine.

Authors:  Charlie Yu Ming Hsu; Hasan Uludağ
Journal:  Nat Protoc       Date:  2012-04-19       Impact factor: 13.491

8.  Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions.

Authors:  Kathryn J Huber-Keener; Brad R Evans; Xingcong Ren; Yan Cheng; Yi Zhang; William N Hait; Jin-Ming Yang
Journal:  Biochem Biophys Res Commun       Date:  2012-06-27       Impact factor: 3.575

9.  Alternative splicing and caspase-mediated cleavage generate antagonistic variants of the stress oncoprotein LEDGF/p75.

Authors:  Terry A Brown-Bryan; Lai S Leoh; Vidya Ganapathy; Fabio J Pacheco; Melanie Mediavilla-Varela; Maria Filippova; Thomas A Linkhart; Rik Gijsbers; Zeger Debyser; Carlos A Casiano
Journal:  Mol Cancer Res       Date:  2008-08       Impact factor: 5.852

10.  An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.

Authors:  Shahir S Rizk; Anna Luchniak; Serdar Uysal; Crista M Brawley; Ronald S Rock; Anthony A Kossiakoff
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.